Page 116 - Haematologica-5

E. Van Den Neste et al.
PLoS One. 2011;6(4):e18856.
32. Hao Y, Chapuy B, Monti S, Sun HH, Rodig
SJ, Shipp MA. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. Clin Cancer Res. 2014;20(10):2674-2683.
33. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best avail- able therapy for myelofibrosis. Blood. 2013;122(25):4047-4053.
34. Falzetti D, Crescenzi B, Matteuci C, et al. Genomic instability and recurrent break- points are main cytogenetic findings in Hodgkin's disease. Haematologica. 1999;84 (4):298-305.
35. Naqvi K, Daver N, Pemmaraju N, et al.
Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clini- cal study. Leuk Lymphoma. 2017;58(4): 866-871.
36. Daver N, Cortes J, Newberry K, et al. Ruxolitinib in combination with lenalido- mide as therapy for patients with myelofi- brosis. Haematologica. 2015;100(8):1058- 1063.
37. Devillier R, Raffoux E, Rey J, et al. Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms. Br J Haematol. 2016;172(4):628- 630.
38. Mayfield JR, Czuchlewski DR, Gale JM, et al. Integration of ruxolitinib into dose-inten- sified therapy targeted against a novel JAK2
F694L mutation in B-precursor acute lym- phoblastic leukemia. Pediatr Blood Cancer. 2017;64(5).
39. HuY,HongY,XuY,LiuP,GuoDH,ChenY. Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC. Apoptosis. 2014;19(11):1627-1636.
40. Ju W, Zhang M, Wilson KM, et al. Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma. Proc Natl Acad Sci USA. 2016;113(6):1624-1629.
41. Zhang M, Mathews Griner LA, Ju W, et al. Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2- dependent adult T-cell leukemia. Proc Natl Acad Sci USA. 2015;112(40):12480-12485.
848
haematologica | 2018; 103(5)